TY - JOUR
T1 - The Society of Thoracic Surgeons Intermacs 2023 Annual Report
T2 - Focus on Magnetically Levitated Devices
AU - Jorde, Ulrich P.
AU - Saeed, Omar
AU - Koehl, Devin
AU - Morris, Alanna A.
AU - Wood, Katherine L.
AU - Meyer, Dan M.
AU - Cantor, Ryan
AU - Jacobs, Jeffrey P.
AU - Kirklin, James K.
AU - Pagani, Francis D.
AU - Vega, J. David
N1 - Publisher Copyright:
© 2024 The Society of Thoracic Surgeons
PY - 2024/1
Y1 - 2024/1
N2 - The 14th Annual Report from The Society of Thoracic Surgeons (STS) Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs) describes outcomes of 27,493 patients with a continuous-flow left ventricular assist device (LVAD) from the past decade (2013-2022). In 2022, 2517 primary LVADs were implanted, of which 2512 (99.8%) were fully magnetically levitated (Mag-Lev) devices. This shift to nearly exclusive use of a Mag-Lev device led us to examine its outcomes compared with contemporary (2018-2022) and historical (2013-2017) non–Mag-Lev cohorts. Patients supported by a Mag-Lev device (n = 10,920) had a higher 1- and 5-year survival of 86% (vs 79% and 81%, P < .0001) and 64% (vs 44% and 44%, P < .0001), respectively, than those receiving non–Mag-Lev devices during the contemporary and historical eras. Over 5 years, freedom from gastrointestinal bleeding (72% vs 60%, P < .0001), stroke (87% vs 67%, P < .0001), and device malfunction/pump thrombus (83% vs 54%, P < .0001), but not device-related infection (61% vs 64%, P = .93), was higher with Mag-Lev devices compared with non–Mag-Lev support during the contemporary era. In this large primacy cohort of real-world patients with advanced heart failure, this report underscores marked improvements in short- and intermediate-term survival and reduction of adverse events with a contemporary Mag-Lev LVAD.
AB - The 14th Annual Report from The Society of Thoracic Surgeons (STS) Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs) describes outcomes of 27,493 patients with a continuous-flow left ventricular assist device (LVAD) from the past decade (2013-2022). In 2022, 2517 primary LVADs were implanted, of which 2512 (99.8%) were fully magnetically levitated (Mag-Lev) devices. This shift to nearly exclusive use of a Mag-Lev device led us to examine its outcomes compared with contemporary (2018-2022) and historical (2013-2017) non–Mag-Lev cohorts. Patients supported by a Mag-Lev device (n = 10,920) had a higher 1- and 5-year survival of 86% (vs 79% and 81%, P < .0001) and 64% (vs 44% and 44%, P < .0001), respectively, than those receiving non–Mag-Lev devices during the contemporary and historical eras. Over 5 years, freedom from gastrointestinal bleeding (72% vs 60%, P < .0001), stroke (87% vs 67%, P < .0001), and device malfunction/pump thrombus (83% vs 54%, P < .0001), but not device-related infection (61% vs 64%, P = .93), was higher with Mag-Lev devices compared with non–Mag-Lev support during the contemporary era. In this large primacy cohort of real-world patients with advanced heart failure, this report underscores marked improvements in short- and intermediate-term survival and reduction of adverse events with a contemporary Mag-Lev LVAD.
UR - http://www.scopus.com/inward/record.url?scp=85177860200&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85177860200&partnerID=8YFLogxK
U2 - 10.1016/j.athoracsur.2023.11.004
DO - 10.1016/j.athoracsur.2023.11.004
M3 - Article
C2 - 37944655
AN - SCOPUS:85177860200
SN - 0003-4975
VL - 117
SP - 33
EP - 44
JO - Annals of Thoracic Surgery
JF - Annals of Thoracic Surgery
IS - 1
ER -